{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'order for hierarchical testing in secondary endpoints will be specified in the SAP before database', 'lock (DBL).', 'Analysis of PFS and ORR will be performed at the time of os analysis. The PFS will be analyzed', 'using the same statistical method as the analysis of OS. The ORR will be analyzed using the', 'Cochran-Mantel-Haenszel test stratified by the same stratification factors used in analysis of OS.', 'An associated odds ratio and 95% CI will be calculated. Objective response rate and the', 'corresponding 95% exact CI will be calculated by Clopper-Pearson method for each treatment', 'arm.', '10.4.5.3. Quality of Life Analysis', 'The change in EORTC QLQ-C30 scores from first assessment to the end of the study will be', 'summarized descriptively at each post-baseline time point and compared using a mixed effect', 'model, if appropriate.', '10.4.5.4. Exploratory Efficacy Endpoint Analysis', 'Relationships between efficacy endpoints and candidate biomarkers will be described.', '10.4.5.5. Subgroup Analyses', 'To determine the consistency of treatment effect across various demographic and baseline', 'subgroups, the estimate of the between-group treatment effect (with a nominal 95% CI) for the', 'primary and key secondary endpoints will be estimated and plotted within each category of the', 'following subgroup variables:', 'Age category (65 years, >65 years)', 'Choice of IC chemotherapy: (1) Antifolate - pemetrexed, (2) Topoisomerase 1', 'inhibitor - topotecan or irinotecan, (3) Nucleoside analogue - gemcitabine, or (4)', 'Vinca alkaloid - vinorelbine', 'Race (white, non-white)', 'ECOG status (0,1)', 'Histology adenocarcinoma/adenosquamous', 'Geographic region (North America, Asia, ROW)', 'Geographic region (Japan, outside of Japan)', 'Prior bevacizumab use(Y/N)', 'Number of prior lines of systemic therapy for recurrent or metastatic disease (1 line or', '>1 line)', '10.4.6.', 'Safety Analysis', 'Safety will be assessed in the overall population. Safety observations and measurements including', 'drug exposure, AEs, laboratory data, vital signs, and ECOG performance status will be', 'summarized and presented in tables and listings.', 'Regeneron Pharmaceuticals, Inc.', 'Page 97 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '10.4.6.1. Adverse Events', 'Definitions', 'For safety variables, 3 observation periods are defined:', 'The pretreatment period is defined as the time from signing the ICF to before the first', 'dose of study drug.', 'The treatment period is defined as the day from first dose of study drug to the day of', 'the last dose of study drug plus 90 days, or to the day before the patient commences', 'another anticancer systemic therapy, whichever comes first.', 'The post-treatment period is defined as the time starting one day after the treatment', 'period ends.', 'Treatment-emergent adverse events (TEAEs) are defined as those that are not present at baseline', 'or represent the exacerbation of a pre-existing condition during the on-treatment period. In', 'addition, the study drug related AEs occurring anytime are considered as TEAEs.', 'Analysis', 'All AEs reported in this study will be coded using the currently available version of the Medical', 'Dictionary for Regulatory Activities (MedDRAR). Coding will be to lowest level terms. The', 'verbatim text, the PT, and the primary SOC will be listed.', 'Summaries of all TEAEs by treatment group will include:', 'The number (n) and percentage (%) of patients with at least 1 TEAE by SOC and PT', 'TEAEs by severity (according to the grading scale outlined in Section 9.5.1), presented', 'by SOC and PT', 'TEAEs by relationship to treatment (related, not related), presented by SOC and PT', 'Treatment-emergent AESIs (defined with a PT or a prespecified grouping)', 'Deaths and other SAEs will be listed and summarized by treatment group. Death due to disease', 'progression will not be considered an AE, but will be reported in efficacy endpoints such as PFS', 'and OS.', 'Treatment-emergent adverse events leading to permanent treatment discontinuation will be listed', 'and summarized by treatment group.', '10.4.6.2. Other Safety', 'Vital Signs', 'Vital signs (temperature, pulse, blood pressure, and respiration rate) will be summarized by', 'baseline and change from baseline to each scheduled assessment time with descriptive statistics.', 'Laboratory Tests', 'Laboratory test results will be summarized by baseline and change from baseline to each scheduled', 'assessment time with descriptive statistics.', 'Regeneron Pharmaceuticals, Inc.', 'Page 98 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}